TIGIT Review Highlights Unresolved Questions for Pancreatic Cancer Immunotherapy

Why It Matters

Understanding TIGIT’s role could unlock new combination strategies for pancreatic cancer, a disease where checkpoint blockade has largely failed. Successful biomarker‑driven development may reshape immunotherapy pipelines for hard‑to‑treat solid tumors.

Key Takeaways

• CITYSCAPE showed tiragolumab benefit in PD‑L1‑selected NSCLC
• TIGIT blocks CD155, opposes CD226, dampening T‑cell activity
• Anti‑TIGIT antibodies remain unproven in pancreatic cancer
• Translational focus: TIGIT/CD155/CD226 profiling to select patients
• Combination safety concerns rise with PD‑1/PD‑L1 blockers

Pulse Analysis

TIGIT, a co‑inhibitory receptor expressed on T cells and NK cells, engages the ligand CD155 to suppress antitumor immunity while counteracting the costimulatory receptor CD226. This dual‑pathway modulation makes TIGIT an attractive target for monoclonal antibody blockade, especially when paired with established PD‑1/PD‑L1 inhibitors. The biological rationale is clear: releasing both checkpoints could amplify cytotoxic responses in tumors that otherwise evade immune surveillance. However, the pathway’s relevance varies across cancer types, and robust translational data are needed to move beyond preclinical promise.

The most compelling clinical signal for anti‑TIGIT therapy emerged from the phase 2 CITYSCAPE trial, where tiragolumab combined with atezolizumab improved outcomes in PD‑L1‑selected metastatic non‑small cell lung cancer. Despite this success, subsequent studies have not replicated efficacy across other solid tumors, and pancreatic ductal adenocarcinoma remains refractory to checkpoint inhibition. The dense stromal matrix, immunosuppressive myeloid cells, and low neoantigen burden in pancreatic cancer create a hostile microenvironment that blunts T‑cell activation, limiting the impact of single‑agent checkpoint blockade and underscoring the need for novel combinatorial approaches.

Future development hinges on identifying biomarkers that predict response to TIGIT inhibition. Quantifying TIGIT, CD155, and CD226 expression, mapping spatial immune phenotypes, and profiling exhaustion markers could stratify patients likely to benefit. Moreover, safety profiling is critical, as combining anti‑TIGIT with PD‑1/PD‑L1 inhibitors may exacerbate immune‑related adverse events. Drug developers are exploring multi‑modal regimens that pair TIGIT blockade with chemotherapy, radiation, stromal modifiers, or vaccine platforms to overcome the pancreatic tumor’s defenses. If these translational hurdles are addressed, TIGIT could become a pivotal component of next‑generation immunotherapy for pancreatic cancer and other resistant solid tumors.